Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | TNF | P01375 | 1/20 | 0.76 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 13/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490321 | 1.00 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862834 | 1.00 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862471 | 1.00 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL29490222 | 1.00 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862473 | 0.88 | RAB9A (0.78) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862863 | 0.88 | RAB9A (0.78) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862865 | 0.86 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862444 | 0.86 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862521 | 0.86 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS | |
| SCHEMBL22862813 | 0.86 | RAB9A (0.76) | RAB9ATNFNOD1EGFRFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | RAB9A 2006/4885TNF 1654/4885NOD1 1284/4885 |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | RAB9A 1715/4885TNF 2254/4885NOD1 3031/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | RAB9A 1715/4885TNF 2254/4885NOD1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.